Jiang Junjie, Peng Wei, Sun Nianzhe, Zhao Deze, Cui Weifang, Lai Yuwei, Zhang Chunfang, Duan Chaojun, Zeng Wei
Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, Hunan, People's Republic of China.
Future Sci OA. 2025 Dec;11(1):2484159. doi: 10.1080/20565623.2025.2484159. Epub 2025 Mar 31.
BACKGROUND: Cancer, influenced by genetics and the environment, involves anoikis, a cell death mechanism upon extracellular matrix detachment crucial for metastasis. Understanding this relationship is key for therapy. We analyze cancer and anoikis trends using bibliometrics. METHODS: A search was conducted from Web of Science Core, PubMed, Scopus and non-English databases such as the CNKI (inception- 21 December 2024). Data analysis employed Microsoft Excel, VOSviewer, CiteSpace, R software, and the online platform (https://bibliometric.com/). RESULTS: 2510 publications were retrieved, with a significant increase in the last decade. China led, the University of Texas system was productive, and the Oncogene Journal was popular. Breast, and colorectal cancers were frequently studied. Among them, representative tumor-related mechanisms were identified, commonalities such as (EMT, ECM, autophagy) and respective specific mechanisms were summarized. CONCLUSION: This bibliometric analysis highlights rapid advances in anoikis research in cancer, emphasizing EMT and FAK pathways' translational potential, guiding targeted therapies, and improving cancer treatment outcomes.
背景:癌症受遗传和环境影响,涉及失巢凋亡,这是一种细胞外基质脱离时的细胞死亡机制,对转移至关重要。理解这种关系是治疗的关键。我们使用文献计量学分析癌症和失巢凋亡的趋势。 方法:从科学网核心库、PubMed、Scopus以及中国知网等非英文数据库(起始时间 - 2024年12月21日)进行检索。数据分析采用微软Excel、VOSviewer、CiteSpace、R软件以及在线平台(https://bibliometric.com/)。 结果:共检索到2510篇出版物,在过去十年中有显著增加。中国排名第一,德克萨斯大学系统产出颇丰,《癌基因杂志》很受欢迎。乳腺癌和结直肠癌是研究较多的癌症。其中,确定了代表性的肿瘤相关机制,总结了诸如(上皮 - 间质转化、细胞外基质、自噬)等共性以及各自的特定机制。 结论:这项文献计量分析突出了癌症失巢凋亡研究的快速进展,强调了上皮 - 间质转化和粘着斑激酶途径的转化潜力,为靶向治疗提供指导并改善癌症治疗结果。
Heliyon. 2024-12-16
Front Immunol. 2023
Front Immunol. 2025-3-14
Front Biosci (Landmark Ed). 2022-8-31
Front Immunol. 2023
Front Cell Infect Microbiol. 2022
Mol Cancer. 2025-1-13
Biomed Pharmacother. 2024-6
Naunyn Schmiedebergs Arch Pharmacol. 2024-10
Pharmacol Ther. 2023-10
Cancers (Basel). 2023-7-25